{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:00:28Z","timestamp":1774677628552,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001907","name":"Washington Square Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001907","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007059","name":"Northwestern University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007059","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["CA133063"],"award-info":[{"award-number":["CA133063"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["CA73507"],"award-info":[{"award-number":["CA73507"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["T32-AI060523"],"award-info":[{"award-number":["T32-AI060523"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["T32-CA079447"],"award-info":[{"award-number":["T32-CA079447"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.antiviral.2012.05.003","type":"journal-article","created":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T20:49:20Z","timestamp":1337201360000},"page":"49-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A"],"prefix":"10.1016","volume":"95","author":[{"given":"Jamie L.","family":"Dargart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamonwan","family":"Fish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Longnecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osman","family":"Cen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2012.05.003_b0005","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/318533a0","article-title":"The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice","volume":"318","author":"Adams","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2012.05.003_b0010","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1084\/jem.190.4.567","article-title":"Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients","volume":"190","author":"Babcock","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2012.05.003_b0015","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1074-7613(00)80622-6","article-title":"EBV persistence in memory B cells in vivo","volume":"9","author":"Babcock","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2012.05.003_b0020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1074-7613(00)00049-2","article-title":"The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell","volume":"13","author":"Babcock","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2012.05.003_b0025","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1099\/vir.0.81906-0","article-title":"Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt\u2019s lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays","volume":"87","author":"Bell","year":"2006","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2012.05.003_b0030","doi-asserted-by":"crossref","first-page":"17945","DOI":"10.1073\/pnas.0907994106","article-title":"Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis","volume":"106","author":"Bieging","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2012.05.003_b0035","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/onc.2008.492","article-title":"Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis","volume":"28","author":"Bultema","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.antiviral.2012.05.003_b0040","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1128\/JVI.74.3.1101-1113.2000","article-title":"Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice","volume":"74","author":"Caldwell","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.05.003_b0045","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1074-7613(00)80623-8","article-title":"Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals","volume":"9","author":"Caldwell","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2012.05.003_b0050","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/1535-7163.MCT-10-0833","article-title":"Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt\u2019s lymphoma","volume":"10","author":"Cen","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.antiviral.2012.05.003_b0055","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1074-7613(00)80511-7","article-title":"Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation","volume":"7","author":"Chan","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2012.05.003_b0060","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00005792-199103000-00005","article-title":"Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency","volume":"70","author":"Cohen","year":"1991","journal-title":"Medicine"},{"key":"10.1016\/j.antiviral.2012.05.003_b0065","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein-Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2012.05.003_b0070","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0166-3542(02)00110-9","article-title":"Inhibition of host kinase activity altered by the LMP2A signalosome-a therapeutic target for Epstein-Barr virus latency and associated disease","volume":"56","author":"Cooper","year":"2002","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2012.05.003_b0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1517\/13543784.14.1.89","article-title":"BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"14","author":"Doggrell","year":"2005","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.antiviral.2012.05.003_b0080","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1084\/jem.194.3.255","article-title":"Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLP-65 signaling module","volume":"194","author":"Engels","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2012.05.003_b0085","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1002\/eji.200535247","article-title":"Analysis of Lyn\/CD22 double-deficient B cells in vivo demonstrates Lyn- and CD22-independent pathways affecting BCR regulation and B cell survival","volume":"35","author":"Ferry","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.antiviral.2012.05.003_b0090","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1128\/jvi.70.9.6216-6226.1996","article-title":"Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction","volume":"70","author":"Fruehling","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.05.003_b0095","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/viro.1997.8690","article-title":"The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction","volume":"235","author":"Fruehling","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2012.05.003_b0100","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1128\/JVI.72.10.7796-7806.1998","article-title":"Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency","volume":"72","author":"Fruehling","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.05.003_b0105","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1097\/00007890-199812270-00012","article-title":"Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease","volume":"66","author":"Green","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.antiviral.2012.05.003_b0110","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2012.05.003_b0115","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0092-8674(95)90171-X","article-title":"Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease","volume":"83","author":"Hibbs","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2012.05.003_b0120","first-page":"279","article-title":"Pre-B-cell colony formation assay","volume":"292","author":"Ikeda","year":"2005","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.antiviral.2012.05.003_b0125","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.virol.2008.11.018","article-title":"The c-Cbl proto-oncoprotein downregulates EBV LMP2A signaling","volume":"385","author":"Ikeda","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2012.05.003_b0130","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/cncr.25656","article-title":"Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.antiviral.2012.05.003_b0135","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrd2135","article-title":"Dasatinib","volume":"5","author":"Kantarjian","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2012.05.003_b0140","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1084\/jem.192.8.1183","article-title":"Burkitt lymphoma in the mouse","volume":"192","author":"Kovalchuk","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2012.05.003_b0145","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0092-8674(00)80373-6","article-title":"In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death","volume":"90","author":"Lam","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2012.05.003_b0150","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/cncr.25690","article-title":"Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives","volume":"117","author":"Lee","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.antiviral.2012.05.003_b0155","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-3-642-01222-8_7","article-title":"Dasatinib","volume":"184","author":"Lindauer","year":"2010","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.antiviral.2012.05.003_b0160","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2012.05.003_b0165","doi-asserted-by":"crossref","first-page":"10941","DOI":"10.1128\/JVI.75.22.10941-10949.2001","article-title":"C-terminal domain of the Epstein-Barr virus LMP2A membrane protein contains a clustering signal","volume":"75","author":"Matskova","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.05.003_b0170","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/1521-4141(200204)32:4<1029::AID-IMMU1029>3.0.CO;2-M","article-title":"The tyrosine kinase Lyn is required for B cell development beyond the T1 stage in the spleen: rescue by over-expression of Bcl-2","volume":"32","author":"Meade","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.antiviral.2012.05.003_b0175","doi-asserted-by":"crossref","first-page":"9115","DOI":"10.1128\/JVI.74.19.9115-9124.2000","article-title":"The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo","volume":"74","author":"Merchant","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.05.003_b0180","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1074-7613(95)80040-9","article-title":"Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases","volume":"2","author":"Miller","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2012.05.003_b0185","first-page":"128","article-title":"Epstein-Barr virus protein LMP2A regulates reactivation from latency by negatively regulating tyrosine kinases involved in sIg-mediated signal transduction","volume":"3","author":"Miller","year":"1994","journal-title":"Infect. Agents Dis."},{"key":"10.1016\/j.antiviral.2012.05.003_b0190","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.4049\/jimmunol.172.7.4133","article-title":"Microarray analysis of Lyn-deficient B cells reveals germinal center-associated nuclear protein and other genes associated with the lymphoid germinal center","volume":"172","author":"Mirnics","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2012.05.003_b0195","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/1074-7613(95)90126-4","article-title":"Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice","volume":"3","author":"Nishizumi","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.antiviral.2012.05.003_b0200","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1158\/1078-0432.CCR-08-2979","article-title":"Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications","volume":"15","author":"Ong","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.antiviral.2012.05.003_b0205","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1086\/315828","article-title":"Epstein-Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads","volume":"182","author":"Qu","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2012.05.003_b0210","unstructured":"Rickinson, A.B., Kieff, E., 2007. Epstein-Barr Virus. In: Knipe, D.M., P.T., H., D.E., G., Lamb, R.A., Martin, M.A., Roizman, B., Straus, S.E. (Eds.), Fields Virology, fifth ed., Lippincott Williams & Wilkins, Philadelphia, pp. 2655\u20132700."},{"key":"10.1016\/j.antiviral.2012.05.003_b0215","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1128\/JVI.00843-08","article-title":"Epstein-Barr virus latent membrane protein 2A preferentially signals through the Src family kinase Lyn","volume":"82","author":"Rovedo","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.05.003_b0220","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2012.05.003_b0225","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1365-2443.2001.00431.x","article-title":"Crk family adaptor proteins trans-activate c-Abl kinase","volume":"6","author":"Shishido","year":"2001","journal-title":"Genes Cells"},{"key":"10.1016\/j.antiviral.2012.05.003_b0230","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.V91.4.1373","article-title":"Epstein-Barr virus (EBV) in endemic Burkitt\u2019s lymphoma: molecular analysis of primary tumor tissue","volume":"91","author":"Tao","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2012.05.003_b0235","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/35095584","article-title":"Epstein-Barr virus: exploiting the immune system","volume":"1","author":"Thorley-Lawson","year":"2001","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.antiviral.2012.05.003_b0240","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMra032015","article-title":"Persistence of the Epstein-Barr virus and the origins of associated lymphomas","volume":"350","author":"Thorley-Lawson","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2012.05.003_b0245","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1128\/jvi.68.11.7374-7385.1994","article-title":"Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state","volume":"68","author":"Tierney","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.05.003_b0250","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ijc.10372","article-title":"Promiscuous expression of Epstein-Barr virus genes in Burkitt\u2019s lymphoma from the central African country Malawi","volume":"99","author":"Xue","year":"2002","journal-title":"Int. J. Cancer"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354212001088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354212001088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:25:41Z","timestamp":1759062341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354212001088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0166354212001088"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2012.05.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2012.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}